Endocrinology, Vol 99, 1097-1106, Copyright © 1976 by Endocrine Society

ARTICLES

Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria

SC Cheng, K Suzuki, W Sadee and BW Harding

Effects of spironolactone, canrenone and canrenoate-K on adrenal cytochrome P450 (P450) and corticosteroid biosynthesis were examined by studying difference spectra, P450 reduction and corticoid hydroxylation in mitochondrial preparations isolated from zona fasciculata and zona glomerulosa of bovine adrenals and from adrenal adenoma and hyperplastic adrenal cortex removed from patients with hyperaldosteronism. All three agents bound to P450 producing type I difference spectra and underwent hydroxylation. They all inhibited 11beta-hydroxylation in bovine adrenal at 30 muM and higher concentrations. Canrenone, the most potent inhibitor, blocked enzyme activity by 60% at a concentration of 60 muM. Spironolactone stimulated P450 reduction. The order of potency of inhibition was found to correlate with the order of affinity of these agents for P450. 11beta- Hydroxylase in human adrenal appeared to be less sensitive to canrenone. All three agents or their hydroxylated metabolites blocked 18-hydroxylation in bovine adrenal at lower concentrations. Canrenoate- K, being the most effective, inhibited 52% at 20 muM. Low concentrations of canrenone (2.5-5.0 muM) were without effect on 11beta- hydroxylase but markedly inhibited 18-hydroxylation (62-76%) in hyperplastic human adrenals. The inhibitors produced mixed type inhibition of 11beta-hydroxylation and competitive type inhibition of 18-hydroxylation. These findings indicate that at low concentrations spironolactone and its major metabolites, canrenone and canrenoate-K, or their hydroxylated metabolites, can directly interfere with the biosynthesis of aldosterone in bovine and certain human adrenal cortical tissue.

This article has been cited by other articles:

				K. Shigematsu, T. Nakagaki, N. Yamaguchi, K. Kawai, H. Sakai, and O. Takahara Analysis of mRNA expression for steroidogenic enzymes in the remaining adrenal cortices attached to adrenocortical adenomas. Eur. J. Endocrinol., June 1, 2008; 158(6): 867 - 878. [Abstract] [Full Text] [PDF]

				K. Shigematsu, K. Kawai, J. Irie, H. Sakai, O. Nakashima, A. Iguchi, J. Shimamatsu, K. Shimamatsu, Y. Kusaba, and O. Takahara Analysis of Unilateral Adrenal Hyperplasia with Primary Aldosteronism from the Aspect of Messenger Ribonucleic Acid Expression for Steroidogenic Enzymes: A Comparative Study with Adrenal Cortices Adhering to Aldosterone-Producing Adenoma Endocrinology, February 1, 2006; 147(2): 999 - 1006. [Abstract] [Full Text] [PDF]

				R. Giordano, M. Bo, M. Pellegrino, M. Vezzari, M. Baldi, A. Picu, M. Balbo, L. Bonelli, G. Migliaretti, E. Ghigo, et al. Hypothalamus-Pituitary-Adrenal Hyperactivity in Human Aging Is Partially Refractory to Stimulation by Mineralocorticoid Receptor Blockade J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5656 - 5662. [Abstract] [Full Text] [PDF]

				E. Arvat, B. Maccagno, R. Giordano, M. Pellegrino, F. Broglio, L. Gianotti, M. Maccario, F. Camanni, and E. Ghigo Mineralocorticoid Receptor Blockade by Canrenoate Increases Both Spontaneous and Stimulated Adrenal Function in Humans J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3176 - 3181. [Abstract] [Full Text] [PDF]

				I. Terai, K. Yamano, N. Ichihara, J. Arai, and K. Kobayashi Influence of spironolactone on neonatal screening for congenital adrenal hyperplasia Arch. Dis. Child. Fetal Neonatal Ed., November 1, 1999; 81(3): 179F - 183. [Abstract] [Full Text]

				J. Born, D. Steinbach, C. Dodt, and H.-L. Fehm Blocking of Central Nervous Mineralocorticoid Receptors Counteracts Inhibition of Pituitary-Adrenal Activity in Human Sleep J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1106 - 1110. [Abstract] [Full Text] [PDF]